Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 8 (2011), Issue 5 (May)

1. The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis.
   J Leukoc Biol, 89(5): 771-83. [Abstract] [Full-text]
2. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.
   Haematologica, 96(5): 681-6. [Abstract] [Full-text]
3. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial.
   Stat Med, 30(11): 1218-29. [Abstract] [Full-text]
4. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity.
   Toxicol In Vitro, 25(4): 937-43. [Abstract] [Full-text]
5. Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization.
   Acta Pharmacol Sin, 32(5): 664-72. [Abstract] [Full-text]
6. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.
   Blood, 117(18): 4863-70. [Abstract] [Full-text]
7. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
   Blood, 117(18): 4881-4. [Abstract] [Full-text]
8. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
   Blood, 117(18): 4716-25. [Abstract] [Full-text]
9. Survey of activated FLT3 signaling in leukemia.
   PLoS One, 6(4): e19169. [Abstract] [Full-text]
10. HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1.
    J Biol Chem, 286(19): 16832-45. [Abstract] [Full-text]
11. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Pediatr Blood Cancer, 57(1): 36-40. [Abstract] [Full-text]
12. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
    Br J Haematol, 153(5): 612-22. [Abstract] [Full-text]
13. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.
    Leukemia, 25(5): 808-13. [Abstract] [Full-text]
14. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing.
    Leukemia, 25(5): 821-7. [Abstract] [Full-text]
15. Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.
    Leukemia, 25(5): 770-80. [Abstract] [Full-text]
16. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha.
    Leukemia, 25(5): 814-20. [Abstract] [Full-text]
17. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
    Leukemia, 25(5): 800-7. [Abstract] [Full-text]
18. Interferon-α in acute myeloid leukemia: an old drug revisited.
    Leukemia, 25(5): 739-48. [Abstract] [Full-text]
19. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.
    Leukemia, 25(5): 792-9. [Abstract] [Full-text]
20. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
    Bone Marrow Transplant, 46(5): 641-9. [Abstract] [Full-text]
21. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
    Bone Marrow Transplant, 46(5): 636-40. [Abstract] [Full-text]
22. Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.
    Bone Marrow Transplant, 46(5): 702-8. [Abstract] [Full-text]
23. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Blood, 117(19): 5257-60. [Abstract] [Full-text]
24. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    J Cancer Res Clin Oncol, 137(6): 997-1003. [Abstract] [Full-text]
25. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases.
    Am J Clin Pathol, 135(6): 915-20. [Abstract] [Full-text]
26. Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants.
    Hum Immunol, 72(6): 503-9. [Abstract] [Full-text]
27. Acute myeloid leukemia with myelodysplasia-related changes with erythroid differentiation involving pleural fluid: a case report and brief cytopathologic review.
    Diagn Cytopathol, 39(6): 451-4. [Abstract] [Full-text]
28. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.
    PLoS One, 6(5): e19798. [Abstract] [Full-text]
29. Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
    Int J Hematol, 93(5): 610-7. [Abstract] [Full-text]
30. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
    Eur J Haematol, 86(6): 531-5. [Abstract] [Full-text]
31. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
    Blood, 117(20): 5306-13. [Abstract] [Full-text]
32. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
    Cancer Immunol Immunother, 60(6): 757-69. [Abstract] [Full-text]
33. HoxA10 activates CDX4 transcription and Cdx4 activates HOXA10 transcription in myeloid cells.
    J Biol Chem, 286(21): 19047-64. [Abstract] [Full-text]
34. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Biol Blood Marrow Transplant, 17(6): 893-900. [Abstract] [Full-text]
35. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Biol Blood Marrow Transplant, 17(6): 875-84. [Abstract] [Full-text]
36. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.
    Biol Blood Marrow Transplant, 17(6): 885-92. [Abstract] [Full-text]
37. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
    Biol Blood Marrow Transplant, 17(6): 852-60. [Abstract] [Full-text]
38. 5-Nitro-2-(3-phenylpropylamino) benzoic acid induced drug resistance to cisplatin in human erythroleukemia cell lines.
    Anat Rec (Hoboken), 294(6): 945-52. [Abstract] [Full-text]
39. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
    Exp Hematol, 39(6): 666-675.e1. [Abstract] [Full-text]
40. Effects of poverty and race on outcomes in acute myeloid leukemia.
    Am J Clin Oncol, 34(3): 297-304. [Abstract] [Full-text]
41. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
    Eur J Cancer, 47(9): 1373-9. [Abstract] [Full-text]
42. MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML.
    Br J Haematol, 153(6): 753-7. [Abstract] [Full-text]
43. Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants.
    Blood, 117(21): 5719-22. [Abstract] [Full-text]
44. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.
    Blood, 117(21): 5612-5. [Abstract] [Full-text]
45. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.
    Blood, 117(21): 5701-9. [Abstract] [Full-text]
46. A key role for KCl cotransport in cell volume regulation in human erythroleukemia cells.
    Life Sci, 88(23): 1001-8. [Abstract] [Full-text]
47. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Jpn J Clin Oncol, 41(6): 820-4. [Abstract] [Full-text]
48. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.
    Med Oncol, 28(2): 544-51. [Abstract] [Full-text]

© 2004-2012 Acute Myeloid Leukemia Research Today. All Rights Reserved.